Curated News
By: NewsRamp Editorial Staff
May 07, 2024
PainReform Advances Non-Opioid Pain Relief Solution PRF-110 in Phase 3 Trial to Combat Opioid Crisis
Discuss on Reddit
Discuss on SubstackTLDR
- PainReform is developing PRF-110, a non-opioid post-operative pain treatment, potentially offering an advantage in the pain management market.
- PRF-110 is currently in a Phase III study in Texas, with progress and future trial plans outlined for soft tissue applications.
- PainReform's PRF-110 aims to transform pain management practices post-surgery, potentially contributing to addressing the opioid crisis.
- PRF-110 is an innovative alternative to traditional opioids, offering up to 72 hours of continuous pain relief directly applied by surgeons.
Impact - Why it Matters
The development of PRF-110 by PainReform has the potential to significantly impact pain management practices post-surgery and address the opioid crisis in the United States. If successful, PRF-110 could provide patients with a safer and more effective alternative to traditional opioids, leading to improved patient outcomes and reduced reliance on addictive pain medications.
Summary
PainReform CEO Ilan Hadar is leading the company's development of PRF-110, a non-opioid post-operative pain treatment that offers up to 72 hours of continuous pain relief. The company is currently conducting a Phase III study in Texas to evaluate the effectiveness and safety of PRF-110, with promising progress made in patient enrollment. If successful, the company plans to submit a New Drug Application in 2026, positioning PRF-110 as a transformative solution in pain management post-surgery.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, PainReform Advances Non-Opioid Pain Relief Solution PRF-110 in Phase 3 Trial to Combat Opioid Crisis
